Australian Study Questions Efficacy Of Bone Cement Treatment
This article was originally published in PharmAsia News
Executive SummaryAn Australian study raises serious questions about the efficacy of a popular treatment for osteoporosis. The study conducted by Australian institutions looked into the value of covering percutaneous vertebroplasty under the Medicare Benefits Scheme. The study concluded that after six months of testing the treatment against a placebo treatment, both sets of patients improved by the same degree. The research also raised the possibility the treatment involving injecting bone cement into broken vertebrae might even do more harm than good because of risks involved. (Click here for more
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.